Parkinson disease: systemic and orofacial manifestations, medical and dental management.

BACKGROUND More than 1.5 million Americans have Parkinson disease (PD), and this figure is expected to rise as the population ages. However, the dental literature offers little information about the illness. TYPES OF STUDIES REVIEWED The authors conducted a MEDLINE search using the key terms "Parkinson's disease," "medical management" and "dentistry." They selected contemporaneous articles published in peer-reviewed journals and gave preference to articles reporting randomized controlled trials. RESULTS PD is a progressive neurodegenerative disorder caused by loss of dopaminergic and nondopaminergic neurons in the brain. These deficits result in tremor, slowness of movement, rigidity, postural instability and autonomic and behavioral dysfunction. Treatment consists of administering medications that replace dopamine, stimulate dopamine receptors and modulate other neurotransmitter systems. CLINICAL IMPLICATIONS Oral health may decline because of tremors, muscle rigidity and cognitive deficits. The dentist should consult with the patient's physician to establish the patient's competence to provide informed consent and to determine the presence of comorbid illnesses. Scheduling short morning appointments that begin 90 minutes after administration of PD medication enhances the patient's ability to cooperate with care. Inclination of the dental chair at 45 degrees, placement of a bite prop, use of a rubber dam and high-volume oral evacuation enhance airway protection. To avoid adverse drug interactions with levodopa and entacapone, the dentist should limit administration of local anesthetic agents to three cartridges of 2 percent lidocaine with 1:100,000 epinephrine per half hour, and patients receiving selegiline should not be given agents containing epinephrine or levonordefrin. The dentist should instruct the patient and the caregiver in good oral hygiene techniques.

[1]  E. D. Hodges,et al.  Management of orofacial manifestations of Parkinson's disease with splint therapy: a case report. , 1993, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

[2]  M. Asanuma,et al.  Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease. , 2008, Current pharmaceutical design.

[3]  Yunling E. Du,et al.  Subthalamic stimulation for Parkinson disease: determination of electrode location necessary for clinical efficacy. , 2005, Neurosurgical focus.

[4]  Dagmar Verbaan,et al.  Assessment of psychiatric complications in Parkinson's disease: The SCOPA‐PC , 2007, Movement disorders : official journal of the Movement Disorder Society.

[5]  E. Yano,et al.  Oral health of patients with Parkinson's disease: factors related to their better dental status. , 2003, The Tohoku journal of experimental medicine.

[6]  C. Clarke,et al.  Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease , 2000, Journal of neurology, neurosurgery, and psychiatry.

[7]  J. Matsumoto,et al.  Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. , 2005, Parkinsonism & related disorders.

[8]  R. Palm,et al.  Selegiline slows the progression of the symptoms of Parkinson disease , 2006, Neurology.

[9]  W. Weiner,et al.  Parkinson's disease. Diagnosis and the initiation of therapy. , 2005, Minerva medica.

[10]  P. Lamey,et al.  Burning mouth in Parkinson's disease sufferers. , 1998, Gerodontology.

[11]  L. Findley,et al.  Abnormality of taste and smell in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[12]  Daniel Tarsy,et al.  BEATING A DEAD HORSE: DOPAMINE AND PARKINSON DISEASE , 2008, Neurology.

[13]  F. Lobbezoo,et al.  Dental implications of some common movement disorders: a concise review. , 2007, Archives of oral biology.

[14]  M. Borg,et al.  The role of radiation therapy in the management of sialorrhea. , 1998, International journal of radiation oncology, biology, physics.

[15]  F. Stocchi Optimising levodopa therapy for the management of Parkinson’s disease , 2005, Journal of neurology.

[16]  K. Kashihara Weight loss in Parkinson’s disease , 2006, Journal of Neurology.

[17]  L. Criddle,et al.  A 79-year-old man with an impalement injury of his face. , 2004, Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association.

[18]  Larry M Baddour,et al.  Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Card , 2007, Circulation.

[19]  R. Hauser,et al.  Advances in the Pharmacologic Management of Early Parkinson Disease , 2007, The neurologist.

[20]  H. Reichmann,et al.  Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients , 2002, Journal of Neural Transmission.

[21]  M. Unosson,et al.  Does l‐dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease? , 2005, Acta neurologica Scandinavica.

[22]  L. B. Aytés,et al.  Salivary gland application of botulinum toxin for the treatment of sialorrhea , 2007 .

[23]  Paolo Barone,et al.  International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[24]  N. Solomon Assessment of tongue weakness and fatigue. , 2004, The International journal of orofacial myology : official publication of the International Association of Orofacial Myology.

[25]  H. Weber,et al.  Clinical outcomes of three Parkinson's disease patients treated with mandibular implant overdentures. , 2000, Clinical oral implants research.

[26]  D. Aarsland,et al.  Cognitive Predictors of Dementia in Parkinson’s Disease: A Community-Based, 4-Year Longitudinal Study , 2005, Journal of geriatric psychiatry and neurology.

[27]  T. Osterberg,et al.  Influence of Parkinson's disease on oral health. , 1992, Acta odontologica Scandinavica.

[28]  J. Fiske,et al.  Parkinson's disease and oral care. , 2000, Dental update.

[29]  K. Marder,et al.  Pooled analysis of tobacco use and risk of Parkinson disease. , 2007, Archives of neurology.

[30]  Neeraj Kumar,et al.  Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. , 2006, Archives of neurology.

[31]  D. Ryglewicz,et al.  Taste responses in patients with Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[32]  T. O'dwyer,et al.  The surgical management of drooling--a 15 year follow-up. , 1997, Clinical otolaryngology and allied sciences.

[33]  W. Weiner,et al.  Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) , 2006, Neurology.

[34]  Jeri Logemann,et al.  Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT®): a pilot study , 2002, INTERSPEECH.

[35]  G Rees Cosgrove,et al.  Experience with Microelectrode Guided Subthalamic Nucleus Deep Brain Stimulation , 2006, Neurosurgery.

[36]  J. Yagiela,et al.  Adverse drug interactions in dental practice: interactions associated with vasoconstrictors. Part V of a series. , 1999, Journal of the American Dental Association.

[37]  E. Tolosa,et al.  The diagnosis of Parkinson's disease , 2006, The Lancet Neurology.

[38]  K. Cook,et al.  Effect of social support on informed consent in older adults with Parkinson disease and their caregivers , 2007, Journal of Medical Ethics.

[39]  A. Lees,et al.  Anticholinergics for symptomatic management of Parkinson's disease. , 2002, The Cochrane database of systematic reviews.

[40]  D. Michalek,et al.  Weight change and body composition in patients with Parkinson's disease. , 1995, Journal of the American Dietetic Association.

[41]  B. Thanvi,et al.  Psychosis in Parkinson’s disease , 2005, Postgraduate Medical Journal.

[42]  S. Shibuya,et al.  Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study. , 2005, Journal of neurosurgery.

[43]  Gang Hu,et al.  Coffee and tea consumption and the risk of Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[44]  K. Kessler,et al.  Differential effects of various treatment combinations on cardiovascular dysfunction in patients with Parkinson's disease , 2004, Acta neurologica Scandinavica.

[45]  E. Winocur,et al.  Drugs and bruxism: a critical review. , 2003, Journal of orofacial pain.

[46]  John G Nutt,et al.  Clinical practice. Diagnosis and initial management of Parkinson's disease. , 2005, The New England journal of medicine.

[47]  K. Kessler,et al.  Determinants of autonomic dysfunction in idiopathic Parkinson’s disease , 2005, Journal of Neurology.

[48]  K. Winge,et al.  Prevalence of bladder dysfunction in Parkinsons disease , 2006, Neurourology and urodynamics.

[49]  G. Paulson,et al.  Relationship of oral microflora with oral health status in Parkinson's disease. , 1994, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

[50]  R. Hilker,et al.  Dementia in Parkinson disease , 2005, Neurology.

[51]  C. Sapienza,et al.  Voluntary Cough Production and Swallow Dysfunction in Parkinson’s Disease , 2008, Dysphagia.

[52]  John G. Nutt,et al.  Diagnosis and Initial Management of Parkinson's Disease , 2005 .

[53]  D. Castell,et al.  Swallowing and esophageal function in Parkinson's disease. , 1995, The American journal of gastroenterology.

[54]  G. Nappi,et al.  Double‐blind, placebo‐controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism , 2003, Movement disorders : official journal of the Movement Disorder Society.

[55]  Donald A Robin,et al.  Perceptions of effort during handgrip and tongue elevation in Parkinson's disease. , 2005, Parkinsonism & related disorders.

[56]  A. Lawrence,et al.  Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease , 2005, Neurology.

[57]  F. Micheli,et al.  Quantitative study of salivary secretion in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[58]  A. Storch,et al.  Increased periodontal pathology in Parkinson's disease , 2006, Journal of Neurology.

[59]  G. Kenangil,et al.  Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline , 2007, Clinical Neurology and Neurosurgery.

[60]  J. Trojanowski,et al.  Nosology of Parkinson’s Disease: Looking for the Way Out of a Quackmire , 2005, Neuron.

[61]  O. Rascol,et al.  A study of salivary secretion in Parkinson's disease. , 1999, Clinical neuropharmacology.

[62]  O. Doğu,et al.  Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease , 2004, Clinical Neurology and Neurosurgery.

[63]  S. Gilbert,et al.  The effects of the combination of chlorhexidine/thymol- and fluoride-containing varnishes on the severity of root caries lesions in frail institutionalised elderly people. , 2004, Journal of dentistry.

[64]  M. Youdim,et al.  Regulation of protein kinase C by the anti‐Parkinson drug, MAO‐B inhibitor, rasagiline and its derivatives, in vivo , 2004, Journal of neurochemistry.

[65]  Anthony H V Schapira,et al.  Treatment options in the modern management of Parkinson disease. , 2007, Archives of neurology.

[66]  D. Goldstein,et al.  Neurocirculatory Abnormalities in Parkinson Disease With Orthostatic Hypotension: Independence From Levodopa Treatment , 2005, Hypertension.

[67]  D. Goff,et al.  Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardi , 2007, Journal of the American Dental Association.

[68]  R. Daroff,et al.  Ophthalmologic features of Parkinson’s disease , 2004, Neurology.

[69]  J. Jankovic Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[70]  M. Hoehn,et al.  Parkinsonism , 1998, Neurology.

[71]  Jack J. Chen,et al.  Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease , 2005, Journal of clinical pharmacology.

[72]  N. Newman,et al.  Ophthalmologic features of Parkinson’s disease , 2004, Neurology.

[73]  J. Atkins,et al.  Laryngeal Findings in Advanced Parkinson's Disease , 2004, The Annals of otology, rhinology, and laryngology.

[74]  H. McDade,et al.  Repeated tongue and hand strength measurements in normal adults and individuals with Parkinson's disease. , 2005, The International journal of orofacial myology : official publication of the International Association of Orofacial Myology.

[75]  Albert Hofman,et al.  Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. , 2005, Archives of neurology.

[76]  Giovanna Pari,et al.  Approach to diagnosis of Parkinson disease. , 2006, Canadian family physician Medecin de famille canadien.

[77]  A. Friedman,et al.  Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. , 2001, Parkinsonism & related disorders.

[78]  M. Panisset,et al.  Salivary production in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[79]  E. Wolters,et al.  Management of non-motor symptoms in advanced Parkinson disease , 2008, Journal of the Neurological Sciences.

[80]  E. D. Barnhart Physicians Desk Reference , 1990 .

[81]  I. Aydogdu,et al.  Electrophysiological evaluation of pharyngeal phase of swallowing in patients with Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[82]  J. Siegfried,et al.  Changes in taste under L-DOPA therapy , 2004, Zeitschrift für Neurologie.

[83]  D. Aarsland,et al.  The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson's disease , 2002, International journal of geriatric psychiatry.

[84]  B. R. Rothwell Dental management of the medically compromised patient , 1987 .

[85]  W. Poewe,et al.  When a Parkinson’s disease patient starts to hallucinate , 2008, Practical Neurology.

[86]  T. Clifford,et al.  The dental awareness and needs of a Parkinson's disease population. , 1995, Gerodontology.

[87]  V. Haroutunian,et al.  The neuropathological basis for depression in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[88]  A. Lees,et al.  Botulinum toxin A as treatment for drooling saliva in PD. , 2000, Neurology.

[89]  Regina Katzenschlager,et al.  Olfaction and Parkinson's syndromes: its role in differential diagnosis , 2004, Current opinion in neurology.

[90]  M. Mori,et al.  Oral Health Conditions in Patients with Parkinson’s Disease , 2004, Journal of epidemiology.

[91]  A. Verma Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease , 2008 .

[92]  B. Seltzer,et al.  Clinical and neuropsychological correlates of impaired awareness of deficits in Alzheimer disease and Parkinson disease: a comparative study. , 2001, Neuropsychiatry, neuropsychology, and behavioral neurology.

[93]  N. Hockstein,et al.  Sialorrhea: a management challenge. , 2004, American family physician.